Vishal Ratkalkar, MD
Nephrology · Newnan, GANPI 1932189503
Payments from drug & device makers
Across 151 payments — averaging $25.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka Pharmaceutical Development & Commercialization, Inc.$718
- AstraZeneca$679
- Amgen$584
- Aurinia Pharma U.S., Inc.$378
- Otsuka America Pharmaceutical, Inc.$341
- Travere Therapeutics, Inc.$205
- plus $956 from 15 others
What the payments were for
- Consulting fees$71819%
- Food & beverage$2,88375%
- Education$2607%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $718 |
| AstraZeneca | 35 | $679 |
| Amgen(2 entities) | 20 | $584 |
| Aurinia Pharma U.S., Inc. | 18 | $378 |
| Otsuka America Pharmaceutical, Inc. | 14 | $341 |
| Travere Therapeutics, Inc. | 22 | $205 |
| Baxter Healthcare | 2 | $152 |
| Bayer | 9 | $150 |
| Ardelyx, Inc. | 6 | $148 |
| Novartis | 5 | $120 |
| Vifor Pharma, Inc. | 4 | $82 |
| Calliditas Therapeutics US Inc. | 2 | $57 |
| OPKO Pharmaceuticals, LLC | 3 | $51 |
| Boehringer Ingelheim | 2 | $47 |
| Mallinckrodt Hospital Products Inc. | 2 | $39 |
| Vantive US Healthcare LLC | 1 | $30 |
| Akebia Therapeutics Inc | 1 | $28 |
| Lilly USA, LLC | 1 | $18 |
| Melinta Therapeutics, LLC | 1 | $14 |
| GSK | 1 | $13 |
| Ultragenyx Pharmaceutical Inc. | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,861 in reported general payments places this provider in the 65th percentile of 388 nephrology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ProsolParenteral Amino Acid 20% No.1 | 115 | $20,175 |
| Torsemide | 12 | $814 |
| Calcitriol | 28 | $556 |
| Losartan Potassium | 15 | $150 |
| Pantoprazole Sodium | 12 | $100 |
| Furosemide | 11 | $74 |
| Alprazolam | 14 | $31 |
| Carisoprodol | 11 | $25 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Newnan
- Ashish DhungelNewnan$104K
- James TumlinLawrenceville$19.8M
- Chinedu NwekeAcworth$3.9M
- Vinayak RamanathLagrange$3.1M
- Harold HubertAugusta$2.8M
- Tamorie SmithColumbus$1.9M
- Barton BrezinaAugusta$1.5M
- Frederic Rahbari OskouiAtlanta$1.5M
- Rajeev ChauhanColumbus$1.1M
- Sagar PanseMacon$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.